Literature DB >> 11470047

What causes the antiphospholipid syndrome?

J T Merrill1.   

Abstract

The antiphospholipid syndrome (APS) is characterized by unpredictable, sporadic, thrombotic events. The cause of the thrombosis is probably multifactorial and may involve disparate effects of the autoantibodies associated with the syndrome, which are known to interfere with various protein regulators of hemostasis. An integrated theory of pathogenesis that accounts for the diversity of autoantibodies and their effects suggests that cellular inflammation or apoptosis within the vasculature may lead to oxidation or turnover in phospholipid membranes. Thus, normally cryptic, functionally important epitopes of phospholipid-binding proteins are subjected to increased exposure to immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470047     DOI: 10.1007/s11926-001-0033-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  98 in total

1.  Multiple retinal arteriolar occlusions associated with coexisting primary antiphospholipid syndrome and factor V Leiden mutation.

Authors:  D Dori; I Beiran; Y Gelfand; N Lanir; J Scharf; B Miller; B Brenner
Journal:  Am J Ophthalmol       Date:  2000-01       Impact factor: 5.258

2.  Antiphospholipid antibody syndrome: treatment.

Authors:  L R Espinoza
Journal:  Lupus       Date:  1996-10       Impact factor: 2.911

Review 3.  Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance.

Authors:  J C Fruchart; G Ailhaud
Journal:  Clin Chem       Date:  1992-06       Impact factor: 8.327

Review 4.  Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis.

Authors:  M I Bokarewa; M Blombäck
Journal:  Semin Hematol       Date:  1997-07       Impact factor: 3.851

5.  The epitopes of apolipoprotein A-I define distinct structural domains including a mobile middle region.

Authors:  Y L Marcel; P R Provost; H Koa; E Raffai; N V Dac; J C Fruchart; E Rassart
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

6.  Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis.

Authors:  S Guis-Sabatier; J Roudier; D Arnoux; A Rochwerger; H Roux; J P Mattei
Journal:  Joint Bone Spine       Date:  2000       Impact factor: 4.929

Review 7.  Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment.

Authors:  M Galli; G Finazzi; T Barbui
Journal:  Ann Med Interne (Paris)       Date:  1996-09

8.  Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia.

Authors:  A Corsini; P Roma; D Sommariva; R Fumagalli; A L Catapano
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

9.  Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies.

Authors:  M Galli; M Daldossi; T Barbui
Journal:  Thromb Haemost       Date:  1994-05       Impact factor: 5.249

10.  Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S.

Authors:  P García de Frutos; R I Alim; Y Härdig; B Zöller; B Dahlbäck
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.